BMO Capital Believes Pfizer (NYSE: PFE) Won’t Stop Here

By Austin Angelo

In a report released today, Alex Arfaei from BMO Capital assigned a Buy rating to Pfizer (NYSE: PFE), with a price target of $37. The company’s shares closed yesterday at $35.06, close to its 52-week high of $35.75.

According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 4.1% and a 62.3% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Kindred Biosciences, Merck & Company, and Eli Lilly & Co.

Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $39.71.

The company has a one year high of $35.75 and a one year low of $29.83. Currently, Pfizer has an average volume of 17.23M.

Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.